Bayer’s $7bn acquisition bond a $27bn hit in worst week of 2014
Bayer, the German pharmaceutical and chemical company, braved the toughest credit market conditions of 2014 this week to complete its biggest bond deal, as investors lost their appetite for risk.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: